Wall Street brokerages expect Agile Therapeutics, Inc. (NASDAQ:AGRX) to post ($0.25) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Agile Therapeutics’ earnings, with estimates ranging from ($0.27) to ($0.24). Agile Therapeutics reported earnings per share of ($0.27) in the same quarter last year, which suggests a positive year over year growth rate of 7.4%. The company is expected to announce its next earnings report on Monday, November 6th.

On average, analysts expect that Agile Therapeutics will report full year earnings of ($1.02) per share for the current financial year, with EPS estimates ranging from ($1.07) to ($0.94). For the next financial year, analysts expect that the company will post earnings of ($1.01) per share, with EPS estimates ranging from ($1.85) to ($0.59). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same period in the previous year, the business posted ($0.29) EPS.

AGRX has been the topic of several recent analyst reports. ValuEngine raised Agile Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 8th. Royal Bank Of Canada set a $8.00 target price on Agile Therapeutics and gave the company a “buy” rating in a research note on Sunday, July 16th. HC Wainwright initiated coverage on Agile Therapeutics in a research note on Wednesday, July 19th. They set a “buy” rating and a $10.00 target price on the stock. Janney Montgomery Scott reissued a “buy” rating and set a $15.00 target price on shares of Agile Therapeutics in a research note on Friday, July 21st. Finally, Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research note on Sunday, July 30th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.20.

ILLEGAL ACTIVITY NOTICE: “Brokerages Anticipate Agile Therapeutics, Inc. (AGRX) Will Announce Earnings of -$0.25 Per Share” was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/23/brokerages-anticipate-agile-therapeutics-inc-agrx-will-announce-earnings-of-0-25-per-share.html.

In other news, Chairman Alfred Altomari purchased 10,000 shares of the business’s stock in a transaction on Friday, August 25th. The stock was acquired at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the acquisition, the chairman now directly owns 161,587 shares of the company’s stock, valued at approximately $539,700.58. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 3.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGRX. Royal Bank of Canada grew its holdings in Agile Therapeutics by 608.0% during the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock valued at $122,000 after buying an additional 27,907 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in Agile Therapeutics during the 2nd quarter valued at approximately $122,000. Susquehanna International Group LLP purchased a new position in Agile Therapeutics during the 2nd quarter valued at approximately $205,000. LMR Partners LLP purchased a new position in Agile Therapeutics during the 2nd quarter valued at approximately $211,000. Finally, Goldman Sachs Group Inc. purchased a new position in Agile Therapeutics during the 2nd quarter valued at approximately $309,000. Institutional investors and hedge funds own 67.59% of the company’s stock.

Shares of Agile Therapeutics (NASDAQ AGRX) traded up 0.20% during mid-day trading on Monday, reaching $5.00. The company’s stock had a trading volume of 152,346 shares. The stock’s market capitalization is $144.03 million. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $7.80. The company’s 50-day moving average price is $4.30 and its 200-day moving average price is $3.80.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.